CD8+ T cells specific for cancer cells are detected within tumours. However, despite their
presence, tumours progress. The clinical success of immune checkpoint blockade and …

The task of epitope discovery and vaccine design is increasingly reliant on bioinformatics
analytic tools and access to depositories of curated data relevant to immune reactions and …

Fewer than 200 proteins are targeted by cancer drugs approved by the Food and Drug
Administration (FDA). We integrate Clinical Proteomic Tumor Analysis Consortium (CPTAC) …

Human tumours typically harbour a remarkable number of somatic mutations. If presented
on major histocompatibility complex class I molecules (MHCI), peptides containing these …

Neoantigens, which are expressed on tumor cells, are one of the main targets of an effective
antitumor T-cell response. Cancer immunotherapies to target neoantigens are of growing …

T-cells have to recognize peptides presented on MHC molecules to be activated and elicit
their effector functions. Several studies demonstrate that some peptides are more …

Throughout the body, T cells monitor MHC-bound ligands expressed on the surface of
essentially all cell types. MHC ligands that trigger a T cell immune response are referred to …

Somatic missense mutations can initiate tumorogenesis and, conversely, anti-tumor
cytotoxic T cell (CTL) responses. Tumor genome analysis has revealed extreme …

This review discusses peptide epitopes used as antigens in the development of vaccines in
clinical trials as well as future vaccine candidates. It covers peptides used in potential …

Genome sequencing has revealed a large number of shared and personal somatic
mutations across human cancers. In principle, any genetic alteration affecting a protein …